Nanomedicine for the prevention, treatment and imaging of atherosclerosis

Mackay, 2004 Antoniades, 2009, Targeting redox signaling in the vascular wall: from basic science to clinical practice, Curr Pharm Des, 15, 329, 10.2174/138161209787354230 Stocker, 2004, Role of oxidative modifications in atherosclerosis, Physiol Rev, 84, 1381, 10.1152/physrev.00047.2003 Naghavi, 2003, From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I, Circulation, 108, 1664, 10.1161/01.CIR.0000087480.94275.97 Goldberg, 2007, Nanostructured materials for applications in drug delivery and tissue engineering, J Biomater Sci Polym Ed, 18, 241, 10.1163/156856207779996931 Antoniades, 2010, Nanoparticles a promising therapeutic approach in atherosclerosis, Cancer Drug Deliv, 7, 303, 10.2174/156720110793360586 Jain, 2001, Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function, J Control Release, 74, 7, 10.1016/S0168-3659(01)00306-6 Qiu, 2006, Polymer architecture drug delivery, Pharm Res, 23, 1, 10.1007/s11095-005-9046-2 Schwendener, 2007, Liposomes in biology and medicine, Adv Exp Med Biol, 620, 117, 10.1007/978-0-387-76713-0_9 Christian, 2009, Polymersome carriers: from self-assembly to siRNA and protein therapeutics, Eur J Pharm Biopharm, 71, 463, 10.1016/j.ejpb.2008.09.025 Harris, 2003, Effect of pegylation on pharmaceuticals, Nat Rev Drug Discov, 2, 214, 10.1038/nrd1033 Shin, 2003, Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG–lipids, J Control Release, 91, 187, 10.1016/S0168-3659(03)00232-3 Zalipsky, 1999, New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine, Bioconjug Chem, 10, 703, 10.1021/bc990031n Rhen, 2005, Antiinflammatory action of glucocorticoids – new mechanisms for old drugs, N Engl J Med, 353, 1711, 10.1056/NEJMra050541 Pepine, 1990, A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group, Circulation, 81, 1753, 10.1161/01.CIR.81.6.1753 Stone, 1989, A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty, Catheter Cardiovasc Diagn, 18, 227, 10.1002/ccd.1810180407 Joner, 2008, Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma, Arterioscler Thromb Vasc Biol, 28, 1960, 10.1161/ATVBAHA.108.170662 Woollard, 2010, Monocytes in atherosclerosis: subsets and functions, Nat Rev Cardiol, 7, 77, 10.1038/nrcardio.2009.228 Chono, 2005, Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice, J Drug Target, 13, 267, 10.1080/10611860500159030 Chono, 2006, Pharmacokinetic analysis of the uptake of liposomes by macrophages and foam cells in vitro and their distribution to atherosclerotic lesions in mice, Drug Metab Pharmacokinet, 21, 37, 10.2133/dmpk.21.37 Homem de Bittencourt, 2007, LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions, Atherosclerosis, 193, 245, 10.1016/j.atherosclerosis.2006.08.049 Tam, 2005, Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE−/− mice, J Lipid Res, 46, 2091, 10.1194/jlr.M500191-JLR200 Duncan, 2003, The dawning era of polymer therapeutics, Nat Rev Drug Discov, 2, 347, 10.1038/nrd1088 Brocchini, 1999 Peng, 2001, Polymer, 42, 2091, 10.1016/S0032-3861(00)00369-4 Duncan, 1994, Polymer conjugates. Pharmacokinetic considerations for design and development, Clin Pharmacokinet, 27, 290, 10.2165/00003088-199427040-00004 Desai, 1996, Gastrointestinal uptake of biodegradable microparticles: effect of particle size, Pharm Res, 13, 1838, 10.1023/A:1016085108889 Photos, 2003, Polymer vesicles in vivo: correlations with PEG molecular weight, J Control Release, 90, 323, 10.1016/S0168-3659(03)00201-3 Moghimi, 2003, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog Lipid Res, 42, 463, 10.1016/S0163-7827(03)00033-X Mulder, 2007, Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG–micelles, Magn Reson Med, 58, 1164, 10.1002/mrm.21315 Briley-Saebo, 2008, Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes, Circulation, 117, 3206, 10.1161/CIRCULATIONAHA.107.757120 Winter, 2006, Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis, Arterioscler Thromb Vasc Biol, 26, 2103, 10.1161/01.ATV.0000235724.11299.76 Winter, 2003, Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging, Cancer Res, 63, 5838 Antoniades, 2010, Nanoparticles: a promising therapeutic approach in atherosclerosis, Cancer Drug Deliv, 7, 303, 10.2174/156720110793360586 Chnari, 2005, Nanoscale anionic macromolecules for selective retention of low-density lipoproteins, Biomaterials, 26, 3749, 10.1016/j.biomaterials.2004.09.038 Nagle, 2003, The further evolution of biotech, Nat Rev Drug Discov, 2, 75, 10.1038/nrd989 Delgado, 1992, The uses and properties of PEG-linked proteins, Crit Rev Ther Drug Carrier Syst, 9, 249 Chapman, 1999, Therapeutic antibody fragments with prolonged in vivo half-lives, Nat Biotechnol, 17, 780, 10.1038/11717 Goodson, 1990, Site-directed pegylation of recombinant interleukin-2 at its glycosylation site, Biotechnology (NY), 8, 343, 10.1038/nbt0490-343 Sato, 2002, Enzymatic procedure for site-specific pegylation of proteins, Adv Drug Deliv Rev, 54, 487, 10.1016/S0169-409X(02)00024-8 Atochina, 1998, Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress, Am J Physiol, 275, L806 Christofidou-Solomidou, 2003, PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress, Am J Physiol Lung Cell Mol Physiol, 285, L283, 10.1152/ajplung.00021.2003 Wiewrodt, 2002, Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells, Blood, 99, 912, 10.1182/blood.V99.3.912 Antoniades, 2010, Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity, Circulation, 122, S66, 10.1161/CIRCULATIONAHA.109.927376 Dikalov, 2011, Cross talk between mitochondria and NADPH oxidases, Free Radic Biol Med, 10.1016/j.freeradbiomed.2011.06.033 Maximov, 2010, Protein–nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia, Nanotechnology, 21, 265103, 10.1088/0957-4484/21/26/265103 Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888 Wang, 2010, Nanoparticle-based delivery system for application of siRNA in vivo, Curr Drug Metab, 11, 182, 10.2174/138920010791110863 Li, 2007, Temporal evolution of gene expression in rat carotid artery following balloon angioplasty, J Cell Biochem, 101, 399, 10.1002/jcb.21190 Kroto, 1985, C60: buckminster fullerene, Nature, 318, 162, 10.1038/318162a0 Bakry, 2007, Medicinal applications of fullerenes, Int J Nanomed, 2, 639 Xiao, 2011, Highly hydroxylated fullerene localizes at the cytoskeleton and inhibits oxidative stress in adipocytes and a subcutaneous adipose-tissue equivalent, Free Radic Biol Med, 10.1016/j.freeradbiomed.2011.05.026 Hsu, 2000, Water-soluble hexasulfobutyl 60 fullerene inhibits plasma lipid peroxidation by direct association with lipoproteins, J Cardiovasc Pharmacol, 36, 423, 10.1097/00005344-200010000-00002 Maeda, 2008, A water-soluble fullerene vesicle alleviates angiotensin II-induced oxidative stress in human umbilical venous endothelial cells, Hypertens Res, 31, 141, 10.1291/hypres.31.141 Walker, 2009, Potential in vitro effects of carbon nanotubes on human aortic endothelial cells, Toxicol Appl Pharmacol, 236, 319, 10.1016/j.taap.2009.02.018 Niwa, 2007, Nanomaterials induce oxidized low-density lipoprotein cellular uptake in macrophages and platelet aggregation, Circ J, 71, 437, 10.1253/circj.71.437 Moller, 2011, Hazard identification of particulate matter on vasomotor dysfunction and progression of atherosclerosis, Crit Rev Toxicol, 41, 339, 10.3109/10408444.2010.533152 Simeonova, 2009, Engineered nanoparticle respiratory exposure and potential risks for cardiovascular toxicity: predictive tests and biomarkers, Inhal Toxicol, 21, 68, 10.1080/08958370902942566 Wickline, 2007, Molecular imaging and therapy of atherosclerosis with targeted nanoparticles, J Magn Reson Imaging, 25, 667, 10.1002/jmri.20866 Demos, 1999, In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement, J Am Coll Cardiol, 33, 867, 10.1016/S0735-1097(98)00607-X Kobayashi, 2003, Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores, Bioconjug Chem, 14, 388, 10.1021/bc025633c Sato, 2001, Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores, Magn Reson Med, 46, 1169, 10.1002/mrm.1314 Loo, 2004, Nanoshell-enabled photonics-based imaging and therapy of cancer, Technol Cancer Res Treat, 3, 33, 10.1177/153303460400300104 Michalet, 2005, Quantum dots for live cells, in vivo imaging, and diagnostics, Science, 307, 538, 10.1126/science.1104274 McAteer, 2011, Magnetic resonance imaging of brain inflammation using microparticles of iron oxide, Methods Mol Biol, 680, 103, 10.1007/978-1-60761-901-7_7 Schmitz, 2000, Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits, Invest Radiol, 35, 460, 10.1097/00004424-200008000-00002 McCarthy, 2006, A macrophage-targeted theranostic nanoparticle for biomedical applications, Small, 2, 983, 10.1002/smll.200600139 Vasan, 2006, Biomarkers of cardiovascular disease: molecular basis and practical considerations, Circulation, 113, 2335, 10.1161/CIRCULATIONAHA.104.482570 Danesh, 2004, C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N Engl J Med, 350, 1387, 10.1056/NEJMoa032804 Mangoni, 2002, Homocysteine cardiovascular disease: current evidence future prospects, Am J Med, 112, 556, 10.1016/S0002-9343(02)01021-5 Wang, 2006, Multiple biomarkers for the prediction of first major cardiovascular events and death, N Engl J Med, 355, 2631, 10.1056/NEJMoa055373 Cui, 2001, Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species, Science, 293, 1289, 10.1126/science.1062711 Wang, 2009, Mini sensing chip for point-of-care acute myocardial infarction diagnosis utilizing micro-electro-mechanical system and nano-technology, Adv Exp Med Biol, 645, 101, 10.1007/978-0-387-85998-9_16 Vogt, 2004, Efficacy of ion-selective probes in early epicardial in vivo detection of myocardial ischemia, Physiol Meas, 25, N21, 10.1088/0967-3334/25/6/N02 Sato, 2006, Cell-based indicator to visualize picomolar dynamics of nitric oxide release from living cells, Anal Chem, 78, 8175, 10.1021/ac061791b Hsiai, 2006, Differentiation of oxidized low density lipoproteins by nanosensors, Sens Actuators B: Chem, 114, 788, 10.1016/j.snb.2005.06.067 Magrez, 2006, Cellular toxicity of carbon-based nanomaterials, Nano Lett, 6, 1121, 10.1021/nl060162e Stern, 2008, Nanotechnology safety concerns revisited, Toxicol Sci, 101, 4, 10.1093/toxsci/kfm169 Zolnik, 2010, Nanoparticles and the immune system, Endocrinology, 151, 458, 10.1210/en.2009-1082 Dobrovolskaia, 2008, Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution, Mol Pharmacol, 5, 487, 10.1021/mp800032f Bosi, 2004, Hemolytic effects of water-soluble fullerene derivatives, J Med Chem, 47, 6711, 10.1021/jm0497489 Domanski, 2004, Influence of PAMAM dendrimers on human red blood cells, Bioelectrochemistry, 63, 189, 10.1016/j.bioelechem.2003.09.023 Shah, 2000, DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers, Int J Pharm, 208, 41, 10.1016/S0378-5173(00)00534-2 Radomski, 2005, Nanoparticle-induced platelet aggregation and vascular thrombosis, Br J Pharmacol, 146, 882, 10.1038/sj.bjp.0706386 Aggarwal, 2009, Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy, Adv Drug Deliv Rev, 61, 428, 10.1016/j.addr.2009.03.009 Ishida, 2007, PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner, J Control Release, 122, 349, 10.1016/j.jconrel.2007.05.015 Wang, 2007, Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes, J Control Release, 119, 236, 10.1016/j.jconrel.2007.02.010 Chen, 1998, Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics, Proc Natl Acad Sci USA, 95, 10809, 10.1073/pnas.95.18.10809 Al-Hanbali, 2006, Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption, J Nanosci Nanotechnol, 6, 3126, 10.1166/jnn.2006.406 Bertholon, 2006, Complement activation by core–shell poly(isobutylcyanoacrylate)–polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide, Pharm Res, 23, 1313, 10.1007/s11095-006-0069-0 Vonarbourg, 2006, Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake, J Biomed Mater Res A, 78, 620, 10.1002/jbm.a.30711